European Union & GT Biopharma

European Union: The European Union is a key market where Imlifidase is conditionally approved and where the PAES study was conducted, leading to the upcoming application for full marketing authorization.

GT Biopharma: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.

European Union: The European Union>>> is a key region where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.

GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.

European Union: The EU is a region where Idefirix has conditional approval, contributing to the product's overall commercial base.

GT Biopharma: GT Biopharma achieved a commercial milestone with the first commercial use of Idefirix in Australia, supporting its growth strategy. The company continues to advance regulatory processes, including the FDA BLA review.

GT Biopharma: GT Biopharma announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted for an oral presentation at the American Transplant Congress, which is a positive development for the company's imlifidase product.